Has Dr Paul Cox been involved in clinical trials or human medical research, and what were the outcomes?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Dr. Paul Alan Cox has led and been associated with multiple human clinical trials testing L‑serine for neurodegenerative diseases: a Phase I safety trial in ALS and a 125‑patient FDA‑approved Phase II trial for mild cognitive impairment launched in August 2022 in collaboration with Houston Methodist (Phase I safety showed L‑serine was safe; Phase II is ongoing) [1] [2]. His Brain Chemistry Labs directs these trials and earlier human data reported slowed functional decline in ALS patients taking 15 g twice daily in a study described by the lab and in related reporting [2] [1].
1. A career that moved from ethnobotany to human trials
Paul Alan Cox is an ethnobotanist who shifted his research to neurodegenerative disease after field studies in Guam and Okinawa; those population studies — and laboratory work tying diet or toxins to pathology — underpinned efforts to test candidate interventions in humans [3] [2]. Brain Chemistry Labs, of which Cox is Executive Director, is the hub for translating those observations into clinical studies [4] [2].
2. What human trials exist and Cox’s visible role
Available reporting describes a Phase I human safety trial of L‑serine in ALS patients that showed the compound to be safe, and a Phase II trial in ALS and separate Phase II efforts in Alzheimer’s/mild cognitive impairment that followed; a specific 125‑patient FDA‑approved Phase II trial for mild cognitive impairment began in August 2022 with Houston Methodist as a collaborator [1] [2]. Fortune’s reporting notes Cox published results from a six‑month clinical study of L‑serine in ALS (Phase I) and that investigators elsewhere were running Phase II trials of ALS and Alzheimer’s using higher daily doses (30 g/day) [1].
3. Reported outcomes: safety and preliminary efficacy signals
Sources report clear safety results from early human work: the Phase I ALS trial “showed once again that L‑serine is safe for humans” [1]. Brain Chemistry Labs and affiliated writeups state that an earlier human trial administering 15 g twice daily to ALS patients “slowed functional decline” [2]. Fortune and the lab highlight these early efficacy signals as promising but not definitive; large Phase III‑style evidence and regulatory approvals are not reported in current sources [1] [2].
4. Where evidence is stronger — and where it isn’t
Preclinical evidence cited by the lab includes non‑human primate and cell studies showing L‑serine slowed formation of tangles and plaques associated with neurodegeneration; these preclinical data helped justify human testing [2]. However, Fortune emphasizes the broader context: Alzheimer’s drug development has a long history of failed trials and regulatory hurdles, and early Phase I/II signals do not equate to proven, approved therapies [1]. Available sources do not present completed Phase III trials or regulatory approvals for L‑serine as an Alzheimer’s or ALS treatment [1] [2].
5. Collaborations, doses, and trial scale
Reporting mentions collaborators and varying dosages: Houston Methodist for the 125‑patient MCI Phase II trial (started Aug 2022), investigators elsewhere running Phase II studies at 30 g/day, and earlier ALS dosing of 15 g twice daily in a trial referenced by Brain Chemistry Labs [2] [1]. The differences in dose and investigator teams indicate multiple independent efforts rather than a single coordinated development program [1] [2].
6. Competing perspectives and implied agendas
Brain Chemistry Labs and Cox’s public materials present L‑serine as a hopeful, low‑risk, diet‑derived therapy translated from ethnobotanical insight [2] [5]. Journalistic coverage (Fortune) places those claims in the realistic, skeptical context of Alzheimer’s research — many promising candidates fail in larger trials — and urges caution about extrapolating early safety or small‑trial efficacy signals [1]. Institutional and promotional sites linked to Cox have an advocacy and translation agenda; independent large‑scale randomized evidence is not yet documented in the sources [2] [5].
7. Remaining questions and limits of available reporting
Sources do not report final Phase II readouts or completed Phase III trials proving clinical benefit, nor any regulatory approvals for L‑serine in ALS or Alzheimer’s as of the cited coverage [1] [2]. Detailed trial protocols, peer‑reviewed full datasets for the described human ALS trial, and long‑term outcome data are not included in the current set of sources — those gaps matter when assessing whether early signals will translate to effective treatments [1] [2].
Bottom line: Dr. Paul Cox has been directly involved in moving L‑serine from field studies and laboratory work into human clinical trials; early human work shows safety and some signals of slowed decline in ALS, and an FDA‑approved 125‑patient Phase II trial for mild cognitive impairment started in 2022, but independent large‑scale efficacy proof and regulatory approval are not reported in the available sources [1] [2].